# Harvard Bioscience Inc: Form 10-Q for the period ended Jun 30, 2026

- Company: [Harvard Bioscience Inc](/companies/hbio.md) (CIK 1123494)
- Form: 10-Q
- Filed: 2026-08-11
- Accepted by EDGAR: Aug 11, 2026, 16:30 ET
- Period: 2026-06-30
- Accession: 0001171843-26-005425
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1123494/000117184326005425/hbio20260630_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1123494/000117184326005425/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2026-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2026-04-01 to 2026-06-30 | $22.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2026-01-01 to 2026-06-30 | $43.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2026-04-01 to 2026-06-30 | $10.1m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2026-01-01 to 2026-06-30 | $18.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2026-04-01 to 2026-06-30 | $12.6m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2026-01-01 to 2026-06-30 | $24.9m | us-gaap:GrossProfit |
| Research and development | 3 months, 2026-04-01 to 2026-06-30 | $2.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2026-01-01 to 2026-06-30 | $4.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2026-04-01 to 2026-06-30 | −$978.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2026-01-01 to 2026-06-30 | −$2.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2026-04-01 to 2026-06-30 | $14.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2026-01-01 to 2026-06-30 | $131.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2026-04-01 to 2026-06-30 | −$2.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2026-01-01 to 2026-06-30 | −$6.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2026-04-01 to 2026-06-30 | −$0.64 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2026-01-01 to 2026-06-30 | −$1.41 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2026-04-01 to 2026-06-30 | −$0.64 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2026-01-01 to 2026-06-30 | −$1.41 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2026-04-01 to 2026-06-30 | 4,526,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2026-01-01 to 2026-06-30 | 4,484,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2026-01-01 to 2026-06-30 | −$337.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2026-01-01 to 2026-06-30 | $1.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2026-06-30 | $6.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2026-06-30 | $46.5m | us-gaap:AssetsCurrent |
| Total assets | at 2026-06-30 | $76.3m | us-gaap:Assets |
| Current liabilities | at 2026-06-30 | $24.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2026-06-30 | $68.9m | us-gaap:Liabilities |
| Long-term debt | at 2026-06-30 | $36.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2026-06-30 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2026-06-30 | $7.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 22,884 characters.

### Forward-Looking Statements

*This Quarterly Report on Form 10-Q contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). The forward-looking statements are principally, but not exclusively, contained in “Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management’s confidence or expectations, and our plans, objectives, expectations, and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “seek,” “expects,” “plans,” “aim,” “anticipates,” “believes,” “estimates,” “is likely,” “projects,” “forecasts,” “predicts,” “intends,” “think,” “potential,” “objectives,” “optimistic,” “strategy,” “goals,” “sees,” “new,” “guidance,” “future,” “continue,” “drive,” “growth,” “long-term,” “develop,” “possible,” “emerging,” “opportunity,” “pursue” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in detail in our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and our other filings with the SEC. You should carefully review all of these factors, as well as other risks described in our public filings, and you should be aware that there may be other factors, including factors of which we are not currently aware, that could cause these differences. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. Harvard Bioscience, Inc. is referred to herein as “we,” “our,” “us,” and “the Company.”*

### Overview

Harvard Bioscience, Inc., a Delaware corporation, is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Our products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations (“CROs”). With operations in the United States, Europe and China, we sell through a combination of direct and distribution channels to customers around the world.

Our business is affected by global and regional economic trends and uncertainties. Our revenue has been and may continue to be negatively affected by our customers forgoing or delaying purchases of our products and services as a result of ongoing uncertainty with respect to the level and timing of funding from the U.S. National Institutes of Health (the “NIH”) or similar government sources. Our business has also been negatively affected by the imposition of increased tariffs on shipments of products between the United States and other countries, and in particular between the United States and China. Our revenue has been and may continue to be negatively affected by greater restrictions and economic disincentives on international trade, including these tariffs. Products and services that we obtain from overseas sources have been and may continue to be affected by these tariffs, resulting in increased costs to our business.

If these trends described above are prolonged or are more severe than anticipated, our business, results of operations, and cash flow may be materially and adversely impacted.

### Strategy

As the life sciences industry accelerates toward New Approach Methodologies (“NAMs”), Harvard Bioscience expects to evolve from a traditional tools provider into a leading enabler of Translational Medicine – positioned to bridge the gap between laboratory research and human clinical success. Building on its gold-standard preclinical foundation, the Company plans to align its portfolio, innovation pipeline, and operating model around four strategic pillars, leading the translational bridge, new product introduction, consumables revenue expansion and operational excellence and disciplined growth.

In addition, we have taken steps to rationalize our product portfolio and improve our operating cost structure. These activities have included the discontinuation of certain non-strategic products, the consolidation of our global operating footprint, and the reduction of our headcount in Europe and North America.

In January 2026, the Company developed a comprehensive plan, referred to as Project Viking, for the strategic consolidation of certain of its manufacturing operations to improve efficiency and support long-term growth.

In June 2026, the Company developed a comprehensive plan for the restructuring of our sales, services and marketing strategy. The Company expects the initiative to deliver approximately $1.0 to $1.2 million in cost savings in 2027, and approximately $0.5 million in annual cost savings for the remainder of fiscal year 2026. The Company expects to incur pre-tax charges related to this restructuring in the range of approximately $0.4 to $0.5 million in the second half of fiscal 2026.

### Selected Results of Operations

### Three months ended June 30, 2026, compared to three months ended June 30, 2025

*(dollars in thousands)*

|  | Three Months Ended June 30, 2026 | % of revenue | 2025 | % of revenue |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $22,727 |  | $20,450 |  |
| Gross profit | 12,630 | 55.6% | 11,533 | 56.4% |
| Sales and marketing expenses | 5,400 | 23.8% | 4,539 | 22.2% |
| General and administrative expenses | 4,617 | 20.3% | 4,262 | 20.8% |
| Research and development expenses | 2,453 | 10.8% | 2,189 | 10.7% |
| Amortization of intangible assets | 820 | 3.6% | 1,162 | 5.7% |
| Other operating expenses | 318 | 1.4% | 200 | 1.0% |
| Interest expense | 1,793 | 7.9% | 1,001 | 4.9% |
| Other expense, net | 125 | 0.6% | 434 | 2.1% |
| Income tax expense | 14 | 0.1% | 28 | 0.1% |

### Revenues

Revenues increased $2.2 million, or 11.1%, to $22.7 million for the three months ended June 30, 2026, compared to $20.5 million for the three months ended June 30, 2025. The increase in revenues was primarily due to increased sales to CROs in the Americas and distributors in Asia Pacific.

### Gross profit

Gross profit increased $1.1 million, or 9.5%, to $12.6 million for the three months ended June 30, 2026, compared with $11.5 million for the three months ended June 30, 2025, primarily due to the revenue increase described above. Gross margin was 55.6% for the three months ended June 30, 2026, compared to 56.4% for the three months ending June 30, 2025. The decrease in gross margin was primarily the result of unfavorable product mix.

### Sales and marketing expenses

Sales and marketing expenses increased $0.9 million, or 19.0%, to $5.4 million for the three months ended June 30, 2026, compared with $4.5 million for the three months ended June 30, 2025. This increase was primarily due to increases in personnel costs as a result of normalizing our cost structure, increases in travel costs, and restructuring costs.

### General and administrative expenses

General and administrative expenses increased $0.3 million, or 8.3%, to $4.6 million for the three months ended June 30, 2026, compared with $4.3 million for the three months ended June 30, 2025. The increase was primarily due to increases in personnel costs as a result of normalizing our cost structure and increases to restructuring costs.

### Research and development expenses

Research and development expenses increased $0.3 million, or 12.1%, to $2.5 million for the three months ended June 30, 2026, compared with $2.2 million for the three months ended June 30, 2025. This increase was primarily due to an increase in personnel costs as a result of normalizing our cost structure.

### Amortization of intangible assets

Amortization of intangible assets included in operating expenses was $0.8 million for the three months ended June 30, 2026, compared with $1.2 million for the three months ended June 30, 2025.

### Other operating expenses

Other operating expenses for the three months ended June 30, 2026 were $0.3 million, compared with $0.2 million for the three months ended June 30, 2025. During the three months ended June 30, 2026, other operating expenses included $0.3 million of restructuring costs in connection with Project Viking. During the three months ended June 30, 2025, other operating expenses included an agent fee of $0.2 million in connection with the receipt of employee retention credits under the CARES Act.

### Interest expense

Interest expense increased $0.8 million, or 79.1%, to $1.8 million for the three months ended June 30, 2026, compared with $1.0 million for the three months ended June 30, 2025. The increase was primarily due to the higher interest rate and amortization of deferred financing costs related to the 2025 Loan Agreement discussed in greater detail in Note 7 (Debt) in the notes to the unaudited condensed consolidated financial statements included herein.

### Other expense, net

Other expense, net for the three months ended June 30, 2026, was $0.1 million which was primarily related to loss on foreign currency. Other expenses, net for the three months ended June 30, 2025, were $0.4 million, which was primarily related to loss on foreign currency.

### Income tax expense (benefit)

The income tax expense was $0.01 million and $0.03 million for the three months ended June 30, 2026 and 2025, respectively. The effective tax rates for the three months ended June 30, 2026 and 2025 were (0.4)% and 1.2%, respectively. The decrease in the effective tax rate during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, was primarily due to the tax effects of stock compensation and changes in accruals and reserves related to prior year tax positions. The Company’s effective tax rate for the three months ended June 30, 2026, was different than the U.S. statutory rate primarily due to changes in valuation allowances associated with the Company’s assessment of the likelihood of the recoverability of deferred tax assets and a benefit recorded for reserves related to uncertain tax positions.

### Six months ended June 30, 2026, compared to six months ended June 30, 2025

*(dollars in thousands)*

|  | Six Months Ended June 30, 2026 | % of revenue | 2025 | % of revenue |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $43,482 |  | $42,224 |  |
| Gross profit | 24,874 | 57.2% | 23,717 | 56.2% |
| Sales and marketing expenses | 10,735 | 24.7% | 9,510 | 22.5% |
| General and administrative expenses | 9,319 | 21.4% | 9,447 | 22.4% |
| Research and development expenses | 4,779 | 11.0% | 4,510 | 10.7% |
| Amortization of intangible assets | 1,640 | 3.8% | 2,322 | 5.5% |
| Goodwill impairment | - | 0.0% | 47,951 | 113.6% |
| Other operating expenses | 553 | 1.3% | 464 | 1.1% |
| Interest expense | 3,521 | 8.1% | 1,934 | 4.6% |
| Other expense, net | 530 | 1.2% | 627 | 1.5% |
| Income tax expense (benefit) | 131 | 0.3% | (426) | -1.0% |

### Revenues

Revenues increased $1.3 million, or 3.0%, to $43.5 million for the six months ended June 30, 2026, compared to $42.2 million for the six months ended June 30, 2025. The increase in revenues was due to increased sales to CROs and pharmaceutical/biotechnology companies in the Americas, Europe, and Asia Pacific, with the largest growth percentage in China.

### Gross profit

Gross profit increased $1.2 million, or 4.9%, to $24.9 million for the six months ended June 30, 2026, compared with $23.7 million for the six months ended June 30, 2025, primarily due to the increase in revenues as well as the associated higher absorption of fixed manufacturing costs. Gross margin increased to 57.2% for the six months ended June 30, 2026, compared with 56.2% for the six months ended June 30, 2025. The increase in gross margin was primarily the result of favorable absorption of fixed manufacturing overhead costs and favorable product mix.

### Sales and marketing expenses

Sales and marketing expenses increased $1.2 million, or 12.9%, to $10.7 million for the six months ended June 30, 2026, compared with $9.5 million for the six months ended June 30, 2025. This increase was primarily due to increased compensation, travel, promotional, and restructuring expenses, partially offset by lower stock-based compensation costs.

### General and administrative expenses

General and administrative expenses decreased $0.1 million, or 1.4%, to $9.3 million for the six months ended June 30, 2026, compared with $9.4 million for the six months ended June 30, 2025. The decrease was primarily due to lower professional fees, partially offset by restructuring costs.

### Research and development expenses

Research and development expenses increased $0.3 million, or 6.0%, to $4.8 million for the six months ended June 30, 2026, compared with $4.5 million for the six months ended June 30, 2025. This increase was primarily due to an increase in compensation and project related costs.

### Amortization of intangible assets

Amortization of intangible assets included in operating expenses decreased $0.7 million, or 29.4%, to $1.6 million for the six months ended June 30, 2026, compared with $2.3 million for the six months ended June 30, 2025.

### Goodwill impairment

We recorded a non-cash goodwill impairment charge of $48.0 million for the six months ended June 30, 2025, following an analysis triggered by the sustained decrease in our stock price, our recent operating results, liquidity risk and the then-current macroeconomic conditions impacting the life sciences industry.

### Other operating expenses

Other operating expenses for the six months ended June 30, 2026 were $0.6 million, compared with $0.5 million for the six months ended June 30, 2025. During the six months ended June 30, 2026, other operating expenses included $0.6 million of restructuring costs in connection with Project Viking. During the six months ended June 30, 2025, other operating expenses included a fee of $0.4 million in connection with the receipt of employee retention credits under the CARES Act and restructuring costs of $0.1 million.

### Interest expense

Interest expense increased $1.6 million, or 82.1%, to $3.5 million for the six months ended June 30, 2026, compared with $1.9 million for the six months ended June 30, 2025. The increase was primarily due to higher average borrowings and a higher effective interest rate during the period compared to prior year.

### Other expense, net

Other expense, net for the six months ended June 30, 2026, was $0.5 million which was primarily related to costs of $0.4 million in connection with the Company’s reverse stock split. Other expenses, net for the six months ended June 30, 2025, were $0.6 million, which was primarily related to loss on foreign currency.

### Income tax expense (benefit)

The income tax expense (benefit) was $0.1 million and $(0.4) million for the six months ended June 30, 2026 and 2025, respectively. The effective tax rates for the six months ended June 30, 2026 and 2025 were (2.1)% and 0.8%, respectively. The lower effective tax rate during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, was primarily due to the tax effect of goodwill impairment.

### Liquidity and Capital Resources

Our primary sources of liquidity are cash and cash equivalents, internally generated cash flow from operations and our shelf registration statement that provides for the issuance of common stock, preferred stock, warrants and units up to an amount equal to $100 million (the “2024 Shelf Registration Statement”). Our expected cash outlays relate primarily to cash payments due under our Loan and Security Agreement (the “2025 Loan Agreement”), entered into with certain financial institutions party thereto as lenders and BroadOak Income Fund, L.P., as the administrative agent and collateral agent on December 17, 2025, as well as salaries, inventory, capital expenditures, and other operating costs. We held cash and cash equivalents of $6.5 million and $8.6 million as of June 30, 2026 and December 31, 2025, respectively. Borrowings outstanding were $40 million as of June 30, 2026 and December 31, 2025, respectively.

On December 17, 2025, the Company entered into the 2025 Loan Agreement and completed a comprehensive refinancing of the Credit Facility, resulting in a new maturity date and improved likelihood of covenant compliance. For additional details on the 2025 Loan Agreement and refinancing, see the discussion in Note 7 to the Condensed Consolidated Financial Statements (Unaudited) included in Part I, Item 1 of this report.

Under the 2025 Loan Agreement, the Company is required to maintain certain financial covenants that are based on financial measures not presented in accordance with U.S. generally accepted accounting principles. The Company was in compliance with these covenants, including the minimum liquidity requirement of $3.0 million at all times and the minimum adjusted EBITDA requirement, measured on a trailing 12-month basis, of at least $6.0 million, as of the end of each of the fiscal quarters ended June 30, 2026 and December 31, 2025.

The Coronavirus Aid, Relief, and Economic Security Act of 2020 provided an employee retention tax credit (“ERTC”) that was a refundable tax credit against certain employer taxes. The Company received ERTC refunds of $3.6 million during the year ended December 31, 2025. The Company’s compliance with the program’s qualifications may be subject to audit until May 2029, which is when the statute of limitation expires.

The following table sets forth the significant sources and uses of cash for the periods set forth below:

*(in thousands)*

|  | Six Months Ended June 30, 2026 | 2025 |
| --- | ---: | ---: |
| Net cash (used in) provided by operating activities | $(337) | $5,741 |
| Net cash used in investing activities | (1,536) | (916) |
| Net cash used in financing activities | (47) | (2,462) |
| Effect of exchange rate changes on cash | (191) | 971 |
| (Decrease) increase in cash and cash equivalents | $(2,111) | $3,334 |

Cash (used in) provided by operations was $(0.3) million and $5.7 million for the six months ended June 30, 2026 and 2025, respectively. Net loss after adding back non-cash items, was $(2.1) million for the six months ended June 30, 2026, compared to $(0.6) million for the six months ended June 30, 2025. Cash flow from operations for the six months ended June 30, 2026 was negatively impacted by cash outflows from inventories of $1.7 million, compared with a favorable impact to cash flows of $1.6 million for the six months ended June 30, 2025. Cash flow from operations for the six months ended June 30, 2026 was also negatively impacted by $0.4 million of prepaid inventory and insurance. The change in accounts receivable for the six months ended June 30, 2026 had a favorable impact of $1.5 million compared to a favorable impact of $3.2 million for the six months ended June 30, 2025.

Cash used in investing activities was $1.5 million and $0.9 million for the six months ended June 30, 2026 and 2025, respectively. Cash used in investing activities for the six months ended June 30, 2026 consisted of $1.1 million of capital expenditures and $0.4 million of capitalized software development. Cash used in investing activities for the six months ended June 30, 2025 consisted of $0.6 million of capital expenditures and $0.3 million of capitalized software development.

Cash used in financing activities was $0.05 million and $2.5 million for the six months ended June 30, 2026 and 2025, respectively. During the six months ended June 30, 2026, we paid $0.1 million in debt issuance costs as part of the 2025 Loan Agreement and we received $0.1 million in cash proceeds from the exercise of warrants.

### Impact of Foreign Currencies

Our international operations in some instances operate as a natural hedge, as we sell our products in many countries and a substantial portion of our revenues, costs and expenses are denominated in foreign currencies, primarily the euro and British pound.

During the three months ended June 30, 2026, changes in foreign currency exchange rates resulted in a favorable effect on revenues of $0.1 million and an unfavorable effect on expenses of $0.1 million. During the six months ended June 30, 2026, changes in foreign currency exchange rates resulted in a favorable effect on revenues of $0.8 million and an unfavorable effect on expenses of $0.1 million.

The (loss) gain associated with the translation of our foreign equity into U.S. dollars included as a component of other comprehensive loss was $(0.1) million and $2.6 million for the three months ended June 30, 2026 and 2025, respectively and $(0.7) million and $3.9 million for the six months ended June 30, 2026 and 2025, respectively.

Currency exchange rate fluctuations included as a component of net loss resulted in currency losses (gain) of $(0.1) million and $0.4 million for three months ended June 30, 2026 and 2025, respectively, and $(0.1) million and $0.6 million for both the six months ended June 30, 2026 and 2025, respectively.

### Critical Accounting Policies

There have been no material changes to the critical accounting policies underlying the accompanying Condensed Unaudited Consolidated Financial Statements and as set forth in Part II, Item 7 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

### Recent Accounting Pronouncements

For information on recent accounting pronouncements impacting our business, see “Recently Issued Accounting Pronouncements Yet to Be Adopted” included in Note 1 to our Condensed Unaudited Consolidated Financial Statements included in Part I, Item 1 of this report.

## Controls and procedures

As filed, 1,984 characters.

#### Evaluation of Disclosure Controls and Procedures

Under the supervision of our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2026.

Disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2026.

#### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the second quarter of fiscal 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

#### Limitations on Effectiveness of Controls and Procedures

In designing and evaluating our controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud within the Company have been detected.

## Risk factors

As filed, 561 characters.

You should carefully consider the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which could materially affect our business, financial position, or future results of operations. The risks described in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial position, or future results of operations.

Filed Aug 11, 2026.
Source: SEC EDGAR, the filing index for accession 0001171843-26-005425. Last ingested by Listed: Nov 11, 2026, 01:53 ET. No prices; not investment advice.
